Legal & General Group
CBIO

Legal & General Group’s Crescent Biopharma CBIO Stock Holding History

Legal & General Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.7K Buy
+2,097
New +$40.9K ﹤0.01% 2870
2021
Q2 		– Sell
-30
Closed -$9K – 3561
2021
Q1 		$9K Hold
30
– – ﹤0.01% 3402
2020
Q4 		$11K Hold
30
– – ﹤0.01% 3303
2020
Q3 		$9K Sell
30
-12
-29% -$4.59K ﹤0.01% 3264
2020
Q2 		$16K Sell
42
-13
-24% -$3.68K ﹤0.01% 3153
2020
Q1 		$13K Sell
55
-13
-19% -$4.97K ﹤0.01% 3079
2019
Q4 		$36K Buy
68
+7
+11% +$3.79K ﹤0.01% 2956
2019
Q3 		$27K Hold
61
– – ﹤0.01% 3016
2019
Q2 		$73K Hold
61
– – ﹤0.01% 2641
2019
Q1 		$76K Buy
61
+4
+7% +$4.58K ﹤0.01% 2573
2018
Q4 		$53K Hold
57
– – ﹤0.01% 2671
2018
Q3 		$82K Hold
57
– – ﹤0.01% 2566
2018
Q2 		$92K Buy
+57
New +$98K ﹤0.01% 2523
2017
Q2 		– Sell
-13
Closed -$7K – 3365
2017
Q1 		$7K Hold
13
– – ﹤0.01% 3222
2016
Q4 		$8K Buy
+13
New +$8.11K ﹤0.01% 3249

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Legal & General Group's CBIO Position: Q2 2026 in Review

Legal & General Group opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 2,097 shares worth $37.7K. The stake represents ﹤0.01% of the portfolio and ranks #2870 among its holdings. This is a return to the name: Legal & General Group previously reported a position in CBIO as recently as Q1 2021.

Legal & General Group first reported a position in CBIO in Q4 2016 and has held it in 15 quarters since. The position peaked at $92K in Q2 2018. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Legal & General Group held 2,097 shares of Crescent Biopharma worth $37.7K as of Q2 2026.
  • Crescent Biopharma was a new Legal & General Group position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2870 holding.
  • Legal & General Group first reported a position in Crescent Biopharma in Q4 2016 and has held it in 15 quarters since.
  • Legal & General Group's Crescent Biopharma position peaked at $92K in Q2 2018.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.